pyrroles has been researched along with col-144 in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 10 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Case, M; Doty, EG; Dowsett, SA; Krege, JH; Pohl, G; Tepper, SJ | 1 |
| Druyts, E; Franklin, M | 1 |
| Agboola, F; Atlas, SJ; Borrelli, EP; Pearson, SD; Rind, DM; Touchette, DR | 1 |
| Croop, R; L'Italien, GJ; Stock, DA | 1 |
| Hussar, DA | 1 |
| Coric, V; Croop, R; Dabirvaziri, P; Deighton, A; Harris, L; Johnston, K; L'Italien, G; Moren, J; Popoff, E; Thiry, A | 1 |
| Diener, HC; Jørgensen, K; Tfelt-Hansen, P | 1 |
| Belger, M; Johansson, E; Polavieja, P; Venkata, SK; Wilhelm, S | 1 |
| Coric, V; Croop, R; Harris, L; Johnston, KM; L'Italien, G; Popoff, E; Powell, L | 1 |
3 review(s) available for pyrroles and col-144
| Article | Year |
|---|---|
Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis.
Topics: Adult; Benzamides; Humans; Migraine Disorders; Network Meta-Analysis; Piperidines; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2022 |
Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings.
Topics: Adult; Benzamides; Double-Blind Method; Female; Humans; Middle Aged; Migraine Disorders; Network Meta-Analysis; Piperidines; Pyridines; Pyrroles; Randomized Controlled Trials as Topic | 2022 |
Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm.
Topics: Adult; Bayes Theorem; Benzamides; Dizziness; Double-Blind Method; Humans; Migraine Disorders; Nausea; Piperidines; Pyridines; Pyrroles; Serotonin Receptor Agonists; Treatment Outcome | 2022 |
7 other study(ies) available for pyrroles and col-144
| Article | Year |
|---|---|
Lasmiditan (Reyvow) and ubrogepant (Ubrelvy) for acute treatment of migraine.
Topics: Animals; Benzamides; Humans; Migraine Disorders; Piperidines; Pyridines; Pyrroles | 2020 |
Pain Freedom at 2 to 8 Hours With Lasmiditan: A Comparison With Rimegepant and Ubrogepant.
Topics: Benzamides; Freedom; Humans; Pain; Piperidines; Pyridines; Pyrroles | 2020 |
ICER's assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine.
Topics: Benzamides; Humans; Migraine Disorders; Piperidines; Pyridines; Pyrroles | 2020 |
The effectiveness and value of novel acute treatments for migraine.
Topics: Analgesics; Benzamides; Calcitonin Gene-Related Peptide; Cost-Benefit Analysis; Drug Costs; Humans; Migraine Disorders; Piperidines; Pyridines; Pyrroles; Quality-Adjusted Life Years; Receptor, Serotonin, 5-HT1F; Receptors, Serotonin; Serotonin 5-HT1 Receptor Agonists; Signal Transduction; Systematic Reviews as Topic; Time Factors; Treatment Outcome | 2020 |
Pain Freedom at 2-8 Hours With Lasmiditan: A Comparison With Rimegepant and Ubrogepant: A Response.
Topics: Benzamides; Freedom; Humans; Pain; Piperidines; Pyridines; Pyrroles | 2020 |
New Drugs 2021, Part 1.
Topics: Antibodies, Monoclonal, Humanized; Benzamides; Dicarboxylic Acids; Drug Approval; Fatty Acids; Heterocyclic Compounds, 4 or More Rings; Humans; Piperidines; Pyridines; Pyrimidines; Pyrroles; United States; United States Food and Drug Administration | 2021 |
Doubtful use of placebo following placebo in recent controlled trials of lasmiditan and ubrogepant for the treatment of migraine attacks.
Topics: Benzamides; Controlled Clinical Trials as Topic; Humans; Migraine Disorders; Piperidines; Pyridines; Pyrroles | 2022 |